Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v10-EN Version v4-EN
Language English English
Date Updated 2019-03-15 2019-02-26
Drug Identification Number 02431130 02431130
Brand name VINORELBINE INJECTION, USP VINORELBINE INJECTION, USP
Common or Proper name 10 mg/ml Vinorelbine (as vinorelbine tartrate) 10 mg/ml Vinorelbine (as vinorelbine tartrate)
Company Name GENERIC MEDICAL PARTNERS INC GENERIC MEDICAL PARTNERS INC
Ingredients VINORELBINE VINORELBINE
Strength(s) 10MG 10MG
Dosage form(s) SOLUTION SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS
Packaging size 5 ML IN CLEAR GLASS VIAL 5 ML IN CLEAR GLASS VIAL
ATC code L01CA L01CA
ATC description PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS
Reason for shortage Delay in shipping of the drug. Disruption of the manufacture of the drug.
Anticipated start date 2019-02-25 2019-02-25
Actual start date
Estimated end date 2019-03-14 2019-03-01
Actual end date 2019-03-14
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments The latest batch of Vinorelbine 10mg/ml 5 ml vials has cleared QA and have been released. Regular supply of both Vinorelbine 10mg/ml 5 ml and 1 ml vials has now been re-established. The allocation process set in place for 5 ml vials with contracted accounts has been removed. GMP did not have a complete shortage during the allocation process. There is already an existing supply of Vinorelbine 10mg/ml 1 ml vials to meet usual national requirements. Short term delay on next delivery of 5ml vial. Supply of 1 ml vial not impacted.
Health Canada comments